SuperNova DiagnosticsÃ‚® to Present at the Rodman & Renshaw Global Investment Conference
WASHINGTON, LONDON and HONG KONG, Sept. 6, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced that Neil J. Campbell, President and CEO, will be presenting at the Rodman & Renshaw Global Investment Conference on September 13, 2011 from 10:50 -11:15 am EDT in the Metropolitan West room of the Waldorf-Astoria in New York, NY.
The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology targeting four industry sectors: human health, animal health, industrial and biodefence/biosecurity. A live webcast and 90 day archive of the presentation will be available at http://www.wsw.com/webcast/rrshq20/spdi.
"Point-of-care and point-of-use diagnostics represent a multi-billion dollar market with an annual growth rate of 20 percent, making it one of the most significant investing and technological opportunities over the next five to 10 years," said Mr. Campbell. "SuperNova is at the forefront of this revolution, having developed our AmpCrystal® platform to provide an array of diagnostic capabilities, from patient treatment to pathogen detection. We welcome the opportunity to showcase our vision and technology to the many investors and industry leaders at the Rodman & Renshaw Global Investment Conference."
About SuperNova Diagnostics®, Inc.
SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while no